EUVIMEDOpdag EUVIMED
ÄquivalenzstudieMultizentrische Studie

Impact of Chronic Kidney Disease on Outcomes With Drug‐Coated Balloons Versus Drug‐Eluting Stents: Insights From the REC‐CAGEFREE I Trial

Xiongwei Bai iD, Haokao Gao, Yuehao Lv, Dongdong Sun, Qiong Wang, Zhiyong Yin, Shangyu Wen, Yuanzhe Jin, Hui Chen iD, Ming Yuan, Lin Zhong, Sigan Hu and 14 more

Catheterization and Cardiovascular Interventions · 2026

DOI: 10.1002/ccd.70348 ↗

At a glance

Äquivalenzstudie in Catheterization and Cardiovascular Interventions, 2026. Written by Xiongwei Bai and 25 co-authors. Institution: Department of Cardiology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China. Major MEDLINE topics: Angioplasty, Balloon, Coronary, Cardiovascular Agents, Coronary Artery Disease, Drug-Eluting Stents. 34 references. Funded by: This trial is an investigator-initiated trial sponsored by Xijing Hospital. The study obtained grant support from Xijing Hospital (Xi'an, China; Grant Number X….

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Data regarding the efficacy and safety of drug‐coated balloons (DCBs) versus drug‐eluting stents (DES) in patients with chronic kidney disease (CKD) remains limited.

Aims

To assess the prognosis of DCB versus DES in patients with and without CKD.

Methods

REC‐CAGEFREE I was an investigator‐initiated, non‐inferiority trial conducted at 43 sites in China, which randomized 2272 patients to paclitaxel‐coated balloons with the option of rescue stenting (DCB group) or second‐generation sirolimus‐eluting stents (DES group) for treating de novo lesions, regardless of vessel diameter. In this pre‐specified subgroup analysis, patients were stratified based on the presence of CKD (kidney damage or estimated glomerular filtration rate < 60 mL/min per 1.73 m²) at baseline. The primary outcome was the device‐oriented composite endpoint (DoCE; including cardiovascular death, target vessel myocardial infarction, and clinically and physiologically‐indicated target lesion revascularization) at 2 years.

Results

Of 2272 patients enrolled, 203 (8.9%) had CKD, with 95 and 108 treated with DCB and DES, respectively. At 2 years, the risk of DoCE was significantly higher in CKD versus non‐CKD patients (22/203 [10.9%] vs . 88/2069 [4.3%], HR IPTW : 2.14, 95% CI: 1.13−4.07, p = 0.022). There was no significant interaction between CKD and treatment allocation ( p interaction = 0.352). Among CKD patients, DoCE occurred in 12/95 (12.7%) and 10/108 (9.3%) patients in the DCB and DES groups (HR IPTW : 1.57, 95% CI: 0.66−3.71, p = 0.317), respectively. Among non‐CKD patients, DoCE occurred in 60/1038 (5.8%) versus 28/1031 (2.7%) patients in the DCB and DES groups (HR IPTW : 2.27, 95% CI: 1.38−3.72, p = 0.002), respectively.

Conclusion

Patients with CKD had worse outcomes compared to those without. DCBs were associated with a higher risk of DoCE than DES, irrespective of CKD status. Trial Registration Unique Identifier: NCT04561739; URL: https://www.clinicaltrials.gov .

Subjects

MeSH terms (MEDLINE)

Angioplasty, Balloon, CoronaryCardiovascular AgentsCoronary Artery DiseaseDrug-Eluting StentsPaclitaxelRenal Insufficiency, ChronicSirolimusAgedFemaleHumansMaleMiddle AgedCardiac CathetersChinaCoated Materials, BiocompatibleGlomerular Filtration RateKidneyPercutaneous Coronary InterventionProsthesis DesignRisk FactorsTime FactorsTreatment Outcome

Author keywords

chronic kidney diseasedrug‐coated balloondrug‐eluting stent

Substances

Cardiovascular AgentsCoated Materials, BiocompatiblePaclitaxelSirolimus

Authors and institutions

  • Department of Cardiology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
  • Department of Cardiology, Tianjin Fourth Central Hospital, Tianjin, China.
  • Department of Cardiology, The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
  • Department of Cardiology, Cardiovascular Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Department of Cardiology, Yantai Yuhuangding Hospital, Yantai, China.
  • Department of Cardiology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.

ORCID profiles: Xiongwei Bai, Hui Chen, Zhexun Lian, Hesong Zeng, Xingqiang He, Patrick W Serruys

Funding

  • This trial is an investigator-initiated trial sponsored by Xijing Hospital. The study obtained grant support from Xijing Hospital (Xi'an, China; Grant Number X…

Cite

APA

Bai, X., Gao, H., Lv, Y., Sun, D., Wang, Q., Yin, Z., Wen, S., Jin, Y., Chen, H., Yuan, M., Zhong, L., Hu, S., Lian, Z., Zeng, H., Pan, H., Liu, J., Fu, G., Zhang, R., He, X., …, & Tao, L. (2026). Impact of Chronic Kidney Disease on Outcomes With Drug‐Coated Balloons Versus Drug‐Eluting Stents: Insights From the REC‐CAGEFREE I Trial. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70348

Vancouver

Bai X, Gao H, Lv Y, Sun D, Wang Q, Yin Z, et al. Impact of Chronic Kidney Disease on Outcomes With Drug‐Coated Balloons Versus Drug‐Eluting Stents: Insights From the REC‐CAGEFREE I Trial. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70348

BibTeX
@article{Bai2026,
  author = {Bai, Xiongwei and Gao, Haokao and Lv, Yuehao and Sun, Dongdong and Wang, Qiong and Yin, Zhiyong and Wen, Shangyu and Jin, Yuanzhe and Chen, Hui and Yuan, Ming and Zhong, Lin and Hu, Sigan and Lian, Zhexun and Zeng, Hesong and Pan, Hongwei and Liu, Jianzheng and Fu, Guotao and Zhang, Ruining and He, Xingqiang and Capodanno, Davide and Garg, Scot and Onuma, Yoshinobu and Wang, Duolao and Serruys, Patrick W and Gao, Chao and Tao, Ling},
  title = {Impact of Chronic Kidney Disease on Outcomes With Drug‐Coated Balloons Versus Drug‐Eluting Stents: Insights From the REC‐CAGEFREE I Trial},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2026},
  doi = {10.1002/ccd.70348}
}
Start for free →